DIA 137 %3 86 2 LT M KAPAKLI

Genel Bilgiler

  • Ticaret Unvanı:
  • DIA. 137 %3.86 2 LT.M.KAPAKLI CIFTLI (MX.)
  • Reçete türü:
  • Normal
  • İçin kullanmak:
  • İnsanlar
  • İlaç türü:
  • allopatik ilaç

Belgeler

  • genel halk için:
  • Bu ürün için bilgi broşürü şu anda mevcut değil, bizim müşteri hizmetleri bir istek gönderebilir ve bunu elde edebiliyoruz en kısa sürede biz size bildireceğiz.


    Genel halk için bilgi broşürü isteyin.

Yerelleştirme

  • Bulunduğu ülkeler::
  • DIA. 137 %3.86 2 LT.M.KAPAKLI CIFTLI (MX.)
    Türkiye
  • Dil:
  • Türkçe

Terapötik bilgiler

  • Terapötik alanı:
  • peritoneal dialytics

Diğer bilgiler

Durum

  • Kaynak:
  • TİTCK - TÜRKİYE İLAÇ VE TIBBİ CİHAZ KURUMU - Türkiye
  • Yetkilendirme durumu:
  • Aktif
  • Yetkilendirme numarası:
  • 8699556675125
  • Yetkilendirme tarihi:
  • 29-01-2013
  • Son Güncelleme:
  • 28-08-2017
  • Bu ürün için bilgi broşürü şu anda mevcut değil, bizim müşteri hizmetleri bir istek gönderebilir ve bunu elde edebiliyoruz en kısa sürede biz size bildireceğiz.

    Genel halk için bilgi broşürü isteyin.

20-10-2018

Scientific Opinion on Flavouring Group Evaluation 200, Revision 1 (FGE.200 Rev.1): 74 α,β‐unsaturated aliphatic aldehydes and precursors from chemical subgroup 1.1.1 of FGE.19

Scientific Opinion on Flavouring Group Evaluation 200, Revision 1 (FGE.200 Rev.1): 74 α,β‐unsaturated aliphatic aldehydes and precursors from chemical subgroup 1.1.1 of FGE.19

Published on: Fri, 19 Oct 2018 00:00:00 +0200 The Panel on Food Additives and Flavourings of the European Food Safety Authority was requested to evaluate the genotoxic potential of 74 flavouring substances from subgroup 1.1.1 of FGE.19 in the Flavouring Group Evaluation 200 Revision 1 (FGE.200 Rev1). In FGE.200, genotoxicity studies were provided for one representative substance, namely hex‐2(trans)‐enal [FL‐no: 05.073], and for other two substances in the same subgroup, namely 2‐dodecenal [FL‐no: 05.03...

Europe - EFSA - European Food Safety Authority Publications

9-11-2011

Danish Pharmacovigilance Update, 20 October 2011

Danish Pharmacovigilance Update, 20 October 2011

In this edition of Danish Pharmacovigilance Update, you can read about: Use of medicines involving a risk of serious and life-threatening skin reactions, the European Medicines Agency to investigate the possible connection between orlistat and rare cases of severe liver toxicity, and the EMA’s review of peritoneal dialysis solutions from Baxter A/S.

Danish Medicines Agency

2-10-2018

Retacrit (Pfizer Europe MA EEIG)

Retacrit (Pfizer Europe MA EEIG)

Retacrit (Active substance: epoetin zeta) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)6481 of Tue, 02 Oct 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/872/T/86

Europe -DG Health and Food Safety

10-7-2018

Puregon (Merck Sharp and Dohme B.V.)

Puregon (Merck Sharp and Dohme B.V.)

Puregon (Active substance: follitropin beta) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)4479 of Tue, 10 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/86/T/97

Europe -DG Health and Food Safety

18-5-2018

EU/3/10/778 (Chiesi Farmaceutici S.p.A.)

EU/3/10/778 (Chiesi Farmaceutici S.p.A.)

EU/3/10/778 (Active substance: Cysteamine bitartrate (gastroresistant)) - Transfer of orphan designation - Commission Decision (2018)3137 of Fri, 18 May 2018 European Medicines Agency (EMA) procedure number: EMA/OD/034/10/T/01

Europe -DG Health and Food Safety